These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 32694315)

  • 1. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ostectomy and Medial Plantar Artery Flap Reconstruction for Charcot Foot Ulceration Involving the Midfoot.
    Sato T; Ichioka S
    J Foot Ankle Surg; 2016; 55(3):628-32. PubMed ID: 26190780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mid-Term Outcomes of Reconstruction of Charcot Foot Neuroarthropathy in Diabetic Patients].
    Kučera T; Grinac M; Valtr O; Šponer P
    Acta Chir Orthop Traumatol Cech; 2019; 86(1):51-57. PubMed ID: 30843514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical treatment of midfoot Charcot neuroarthropathy with osteomyelitis in patients with diabetes: a systematic review.
    Ramanujam CL; Stuto AC; Zgonis T
    J Wound Care; 2020 Jun; 29(Sup6):S19-S28. PubMed ID: 32530758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramedullary foot fixation for midfoot Charcot neuroarthropathy.
    Lamm BM; Siddiqui NA; Nair AK; LaPorta G
    J Foot Ankle Surg; 2012; 51(4):531-6. PubMed ID: 22632840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Diabetic Charcot Patients With and Without Foot Wounds.
    Wukich DK; Sadoskas D; Vaudreuil NJ; Fourman M
    Foot Ankle Int; 2017 Feb; 38(2):140-148. PubMed ID: 27923212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
    Su HY; Yang CY; Ou HT; Chen SG; Chen JC; Ho HJ; Kuo S
    JAMA Netw Open; 2023 Jan; 6(1):e2250639. PubMed ID: 36633847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surgical treatment of the Charcot foot : long-term results and systematic review].
    Hartig N; Krenn S; Trnka HJ
    Orthopade; 2015 Jan; 44(1):14-24. PubMed ID: 25586504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deformity and Clinical Outcomes Following Operative Correction of Charcot Foot: A New Classification With Implications for Treatment.
    Pinzur MS; Schiff AP
    Foot Ankle Int; 2018 Mar; 39(3):265-270. PubMed ID: 29172758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors Associated With Major Lower Extremity Amputation After Osseous Diabetic Charcot Reconstruction.
    Elmarsafi T; Anghel EL; Sinkin J; Cooper PS; Steinberg JS; Evans KK; Kim PJ; Attinger CE
    J Foot Ankle Surg; 2019 Mar; 58(2):295-300. PubMed ID: 30850098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis.
    Abdel Khalik H; Humphries B; Zoratti M; Axelrod D; Kruse C; Ristevski B; Rajaratnam K; Gardner M; Tarride JÉ; Johal H
    Clin Orthop Relat Res; 2022 Oct; 480(10):2013-2026. PubMed ID: 35507306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost comparison: limb salvage versus amputation in diabetic patients with charcot foot.
    Gil J; Schiff AP; Pinzur MS
    Foot Ankle Int; 2013 Aug; 34(8):1097-9. PubMed ID: 23493775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes and Complications of Midfoot Charcot Reconstruction With Intramedullary Beaming.
    Ford SE; Cohen BE; Davis WH; Jones CP
    Foot Ankle Int; 2019 Jan; 40(1):18-23. PubMed ID: 30284492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous surgical repair of a tibialis anterior tendon rupture and diabetic charcot neuroarthropathy of the midfoot: a case report.
    Stapleton JJ
    Clin Podiatr Med Surg; 2013 Oct; 30(4):599-604. PubMed ID: 24075138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary Results of Primary Gastrocnemius-Soleus Recession for Midfoot Charcot Arthropathy.
    Laborde JM; Philbin TM; Chandler PJ; Daigre J
    Foot Ankle Spec; 2016 Apr; 9(2):140-4. PubMed ID: 26395022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.